Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Return on Equity (2019 - 2025)

aTYR PHARMA's Return on Equity history spans 7 years, with the latest figure at 1.05% for Q4 2025.

  • For Q4 2025, Return on Equity fell 5.0% year-over-year to 1.05%; the TTM value through Dec 2025 reached 1.05%, down 5.0%, while the annual FY2025 figure was 1.13%, 28.0% down from the prior year.
  • Return on Equity reached 1.05% in Q4 2025 per ATYR's latest filing, down from 1.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.3% in Q4 2021 to a low of 1.05% in Q4 2025.
  • Average Return on Equity over 5 years is 0.66%, with a median of 0.62% recorded in 2022.
  • Peak YoY movement for Return on Equity: increased 24bps in 2022, then plummeted -47bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.3% in 2021, then plummeted by -108bps to 0.63% in 2022, then increased by 7bps to 0.58% in 2023, then crashed by -73bps to 1.0% in 2024, then dropped by -5bps to 1.05% in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Return on Equity are 1.05% (Q4 2025), 1.02% (Q3 2025), and 0.94% (Q2 2025).